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Plasma membrane Ca2þ-ATPase (PMCA) plays a vital role in maintaining cytosolic calcium concentration
([Ca2þ]i). Given that many diseases have modiﬁed PMCA expression and activity, PMCA is an important
potential target for therapeutic treatment. This study demonstrates that the non-toxic, naturally-oc-
curring polyphenol resveratrol (RES) induces increases in [Ca2þ]i via PMCA inhibition in primary dermal
ﬁbroblasts and MDA-MB-231 breast cancer cells. Our results also illustrate that RES and the ﬂuorescent
intracellular calcium indicator Fura-2, are compatible for simultaneous use, in contrast to previous
studies, which indicated that RES modulates the Fura-2 ﬂuorescence independent of calcium con-
centration. Because RES has been identiﬁed as a PMCA inhibitor, further studies may be conducted to
develop more speciﬁc PMCA inhibitors from RES derivatives for potential therapeutic use.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Plasma membrane Ca2þ-ATPase (PMCA) plays a critical role in
maintaining the cytosolic calcium concentration ([Ca2þ]i) in cells
by extruding calcium from the cytosol into the extracellular space
utilizing energy from ATP hydrolysis. PMCA consists of 10 trans-
membrane α-helices and 2 large cytosolic loops [1]. PMCA is part
of a series of pumps and channels that maintain a calcium con-
centration gradient with a homeostatic [Ca2þ]i of 100 nM. In
contrast to the cytosol, the endoplasmic reticulum (ER) and ex-
tracellular milieu have calcium concentrations of approximately
1 mM. The elevated ER calcium concentration is sustained by the
sarcoendoplasmic reticular Ca2þ-ATPase (SERCA), which hydro-
lyzes ATP to transfer calcium from the cytosol to the ER. Channels
on the ER membrane (inositol 1,4,5-trisphosphate (IP3) and rya-
nodine receptors) and plasma membrane (voltage-gated calcium
channels, store-operated channels, and receptor-operated chan-
nels), when open, enable calcium to move down the concentrationB.V. This is an open access article u
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ealey).gradient from the ER or extracellular space into the cytosol. When
[Ca2þ]i rises above the resting concentration, PMCA expels cal-
cium from the cytosol into the extracellular space. Together, these
pumps and channels facilitate the use of Ca2þ as an important
signaling mechanism inside the cell [2].
Changes in [Ca2þ]i regulate critical cellular functions such as
apoptosis, muscle contraction, neuronal synapse ﬁring, and cel-
lular motility [2]. The cellular response to [Ca2þ]i modulation is
dictated by the duration, magnitude, subcellular location, and the
Ca2þ-binding protein expression proﬁle of each cell [3,4]. PMCA
activation controls the location, duration and magnitude of the
changes in [Ca2þ]i, and thereby helps determine the cellular re-
sponse to the calcium ﬂux.
Because PMCA is a critical component in deﬁning [Ca2þ]i, ge-
netic mutations, overexpression, down-regulation, dysregulation,
and inhibition of PMCA have an array of biological effects in
mammalian cells. Alzheimer's disease, hypertension, male in-
fertility, cardiovascular disease, deafness, diabetes, and cancer
have all been correlated with altered PMCA activity [5–9]. More
speciﬁcally, some of these diseases are characterized by modulated
expression or activity of the four separate PMCA isoforms. For
example, upregulation of PMCA is found in several gastric (KATO-
III) and colon (HT-29, Caco-2, DLD-1, LS-174 T) cancer cell types
during cell differentiation as well as in several breast cancer cell
types (MDA-MB-231, T47D) [6,10,11]. Therapeutic options aiming
to inhibit PMCA could offer new treatment options for cancers and
other diseases with upregulated PMCA proﬁles as PMCA inhibitionnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[2]. Current inhibitors of PMCA have signiﬁcant off-target effects
due in part to a lack of isoform-speciﬁc inhibition [7]. The dis-
covery of an additional PMCA inhibitor is an important step in the
development of a more isoform-speciﬁc treatment for diseases
exhibiting modulated PMCA proﬁles.
Resveratrol (trans-3, 4′, 5-trihydroxystilbene) (RES), a poly-
phenolic, cell-permeable phytoalexin found in grapes, peanuts and
berries, exhibits chemotherapeutic, anti-aging, and cardioprotec-
tive properties [12–14], while exhibiting minimal toxicity in hu-
mans and animal models [15,16]. One possible explanation for the
pleiotropic biologic effects of RES is that RES modulates calcium
signaling. RES has been shown to increase [Ca2þ]i in breast cancer
cells [17] and modulate the magnitude and duration of the calcium
signal in excitable cells, such as neurons and muscle [18]. However,
the mechanism by which the increase in [Ca2þ]i is induced is
unclear. In this study, we use a PMCA activity assay [19] to assess if
RES directly inhibits PMCA and thereby induces increases in
[Ca2þ]i in both normal and cancerous cell lines. This study de-
monstrates that RES inhibits PMCA activity in both normal pri-
mary dermal ﬁbroblasts (PDF) and MDA-MB-231 (MDA) breast
cancer cells.2. Materials and methods
The MDA-MB-231 human breast cancer (HTB-26) (MDA) and
human primary dermal ﬁbroblast (PCS-201–012) (PDF) cell lines
were purchased from ATCC (Manassas, VA). The passage numbers
of MDA cells used in experiments ranged from 10 to 35. Fura-2-
Acetoxymethyl ester (14591) (Fura-2), thapsigargin (10522) (TG),
(-)-epigallocatechin gallate (70935) (EGCG), quercetin
(10005169), trans-resveratrol (70675) (RES), and BAPTA-Acetox-
ymethyl ester (15551) (BAPTA) were purchased from Cayman
Chemical (Ann Arbor, MI). Lanthanum (III) chloride heptahydrate
(LaCl3) (262072) was purchased from Sigma-Aldrich (St. Louis,
MO). Fura-2, pentasodium salt (50032) was purchased from
Biotium (Hayward, CA).
2.1. Cell culture
Both MDA and PDF cells were cultured in Dulbecco's Modiﬁed
Eagle medium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum (FBS) and 1% antibiotic-antimycotic. Cells were
cultured at 37° C in 5% CO2.
2.2. Intracellular calcium imaging
Cells were prepared for imaging by seeding at a density of
20,000 (PDF) or 30,000–40,000 (MDA) cells per well in an 8-well
chamber Lab-Tek #1.0 Borosilicate Coverglass (Thermo Scientiﬁc,
Rochester, NY). Cells were grown for 48–72 h after initial seeding.
No signiﬁcant changes were recorded as a result of variation in
initial cell density or time allowed for cells to grow. Prior to ima-
ging, cells were washed twice with 1:1 FBS:PBS solution. Cells
were then incubated in Ringer solution (NaCl 150 mM, glucose
10 mM, HEPES 5 mM, KCl 5 mM, MgCl2 1 mM, CaCl2 2 mM, pH 7.4)
with 8 mM Fura-2 for 15 min at 37° C in 5% CO2. Where indicated,
20 mM BAPTA was co-loaded with Fura-2. The Fura-2/Ringer so-
lution was then removed, and cells were incubated in fresh Ringer
solution for 30 min at 37° C in 5% CO2. Ringer solution was then
removed and replaced with a Ca2þ-free buffer which was also
used as vehicle for treatments. The Ca2þ-free buffer used was ei-
ther Ca2þ- and Mg2þ-free Hank's Balanced Salt Solution (HBSS) or,
if treating with LaCl3, a Ca2þ , Mg2þ , and phosphate-free HEPES
buffer (NaCl 150 mM, glucose 10 mM, KCl 5 mM, HEPES 5 mM,10 mM EGTA, pH 7.4) to prevent La3þ ions from complexing with
phosphate ions in HBSS. Cells were imaged following Fura-2
loading with an Olympus IX51 inverted microscope. All treatments
were manually pipetted into the wells in 100 mL increments at the
indicated time points. In all trials, cells were imaged for 1 min
before the ﬁrst treatment was added in order to establish a
baseline. Subsequently, the cells were treated with 5 mM TG. In all
trials, RES, LaCl3 and EGCG were dissolved in 1% DMSO in vehicle.
Quercetin was dissolved in 2% DMSO in vehicle. Other details
concerning speciﬁc treatments are included in the Results section.
Data acquired from intracellular calcium imaging was analyzed
with CellSens software by Olympus. Regions of interest (ROI) re-
presenting 1 cell each were selected from each individual ex-
periment and analyzed for changes in [Ca2þ]i. The resulting data
from at least 10 ROIs per trial were then normalized (nZ3).
2.3. Emission spectra
Spectra measurements were taken by exciting at 340 nm and
380 nm while collecting the emission spectrum from 400 to
650 nm in Ca2þ-free and 1 mM Ca2þ PBS buffers. RES and Fura-2
ﬂuorescence were measured on the BMG LABTECH FLUOstar OP-
TIMA plate reader (BMG LABTECH Inc., Cary, NC). Triplicate 100 mL
solutions were made and placed on a Greneir Bio-One Cellstar 96-
well plate. Measurements of the Ca2þ-containing solution (1 mM
CaCl2 in PBS), and Ca2þ-free solution (10 mM EGTA in PBS) with
DMSO concentrations of 0.001%, 0.01%, 0.025%, 0.05%, 0.075%, or
0.1% were used as blanks. The Ca2þ-containing solution and
Ca2þ-free solution were then treated to make up a 5 mM Fura-2-
pentasodium salt solution with either 0, 1, 10, 25, 50, 75 or 100 mM
RES. Spectra measurements were taken by exciting at 340 nm and
380 nm and collecting emissions at 510 nm.
2.4. Statistical analysis
All P values were calculated using a two-tailed t-test. P values
from intracellular calcium imaging experiments were calculated
by comparing the peak magnitude of [Ca2þ]i of each treatment to
the vehicle control. Statistical signiﬁcance was determined by
po0.01.3. Results
3.1. RES inhibits PMCA leading to an increased [Ca2þ]i
We tested RES-induced PMCA inhibition because of the po-
tential RES has as a therapeutic for PMCA-modulated diseases. Our
interest in MDA-MB-231 cells stems from previous research that
indicated PMCA upregulation in this cell type [6]. Previously, it was
demonstrated that in MDA cells, RES had an indirect effect on
PMCA by activating its degradation [17]. Additionally, RES has been
shown to increase [Ca2þ]i in many cell types, including MDA cells
[17,20–22]. Because of evidence supporting interactions between
RES and PMCA, in this study, we use a PMCA activity assay to
explore the RES-induced calcium signal [19]. We studied MDA cells
while using PDF cells as a control to determine the direct effect of
RES on PMCA inhibition in cells with and without a mutated PMCA
proﬁle.
As described in a previous study, we isolated endogenous
PMCA activity [19]. We used Ca2þ-free media to eliminate the
possibility that changes in [Ca2þ]i were due to an inﬂux of Ca2þ
from the extracellular space. The SERCA pump inhibitor thapsi-
gargin (TG) was used to induce a rise in [Ca2þ]i (Fig. 1). The TG-
induced increase in [Ca2þ]i is due to Ca2þ leaking from the ER,
paired with the inhibited reuptake of Ca2þ by SERCA pumps. The
Fig. 1. PMCA activity is inhibited by RES. Cells were monitored for changes in [Ca2þ]i for 15 min using Fura-2. Graphs depict changes in [Ca2þ]i as measured by 340 nm/
380 nm ratio signal intensity. PMCA inhibition with LaCl3 (A) (arrows mark addition of 5 mM TG and 1 mM LaCl3 at 1 min and 6 min, respectively). LaCl3 induced an increase
in [Ca2þ]i in PDF (blue) and MDA (black) cell types as compared to vehicle only treatment in the respective cell types (PDF cells represented by green, MDA cells represented
by red), indicative of PMCA inhibition. To ensure there were no calcium independent effects, BAPTA and Fura-2 were co-loaded into cells (B) (arrows mark addition of 5 mM
TG and 50 mM RES at 1 min and 6 min, respectively). PMCA inhibition by RES (C), (arrows mark addition of 5 mM TG and 100 mM RES at 1 min and 6 min, respectively) in both
PDF (blue) and MDA (black) cells. RES induced a statistically signiﬁcant rise in [Ca2þ]i as compared to a vehicle only treatment (* signiﬁes a statistically signiﬁcant difference
from respective vehicle controls at po0.01) in the respective cell types (PDF cell vehicle treatment represented by green, MDA cell vehicle treatment represented by red).
RES dose-dependent PMCA inhibition (D). Arrows mark addition of 5 mM TG and followed by either 1 (red), 10 (green), 20 (blue), 50 (yellow), or 100 mM (black) RES at 1 min
and 6 min, respectively. RES induced statistically signiﬁcant increases in [Ca2þ]i (* signiﬁes a statistically signiﬁcant increase from vehicle control (violet) at po0.01) in
50 mM and 100 mM RES treatments.
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[Ca2þ]i changes were measured using Fura-2, a Ca2þ-binding,
dual-excitation ﬂuorescent compound [23]. Fura-2 is excited at
380 nm when Ca2þ is not bound and at 340 nm when Ca2þ is
bound. We measured relative [Ca2þ]i by loading Fura-2 into cells,
alternately exciting Fura-2 at 340 nm and 380 nm, and measuring
emission at 510 nm.
As shown in Fig. 1, TG was added in all experiments after 1 min
of imaging, followed by a treatment of RES or LaCl3, a known
PMCA inhibitor [24], 5 min after TG addition. As a positive control
for PMCA inhibition, we treated MDA and PDF cells with 1 mM
LaCl3 (Fig. 1A) and measured changes in relative [Ca2þ]i. Each
treatment with LaCl3 induced an increase in [Ca2þ]i in MDA and
PDF cells, though this did not yield statistically signiﬁcant results
because of the variability of the peak magnitude of [Ca2þ]i, which
was used to quantify the results in Fig. 1.
To determine if there were any calcium-independent effects of
TG or RES on Fura-2 ﬂuorescence, we co-loaded both cell types
with Fura-2 and 20 mM BAPTA (a cell-permeable calcium chelator).
Co-loaded cells were treated with TG and 50 mM RES (Fig. 1B).
Neither TG nor RES elicited a response in the [Ca2þ]i of co-loaded
cells in either cell type, indicating that neither TG nor RES
modulated Fura-2 ﬂuorescence independent of changes in [Ca2þ]i.
Upon treatment with 100 mM RES in Fura-2 loaded cells, both MDA
and PDF cell lines responded with a signiﬁcant increase in [Ca2þ]i
compared to vehicle treatments (po0.01) (Fig. 1C), similar to the
increase seen upon treatment with LaCl3. We also found thatPMCA inhibition by RES is dose-dependent in MDA cells (Fig. 1D).
Similar in design to the above experiments, we treated MDA cells
5 min after TG treatment with varying concentrations of RES (1, 10,
20, 50, or 100 mM). At the concentrations of 50 and 100 mM, RES
induced signiﬁcant increases in [Ca2þ]i (po0.01). Our ﬁndings
indicate that at 50 and 100 μM, RES induces PMCA inhibition.
3.2. RES PMCA inhibition is unique in comparison to similar
polyphenols
Quercetin and epigallocatechin gallate (EGCG) are systemically
nontoxic, naturally-occurring polyphenols that share structural
characteristics with RES (Fig. 2A–C) [25,26]. Treatment with
quercetin and EGCG was designed to assess if these compounds,
which have chemical makeup similar to RES, also have a similar
inhibitory effect upon PMCA. Treatment of PDF (Fig. 2D) and MDA
cells (Fig. 2E) with either 100 mM quercetin or EGCG following TG
treatment produced a change in [Ca2þ]i that was statistically dif-
ferent from that induced by RES. The lack of apparent PMCA in-
hibition demonstrated by two similar compounds, EGCG and
quercetin, suggests that PMCA inhibition is unique to RES.
3.3. Calcium independent effects of RES on Fura-2
Previous studies have shown that RES elicits a calcium-in-
dependent increase of the calcium-bound (340 nm) Fura-2 signal
through an additive ﬂuorescent effect without exhibiting a change
Fig. 2. PMCA inhibition by RES is unique among polyphenols. Structures of resveratrol (A), quercetin (B), and epigallocatechin gallate (EGCG) (C). PDF cells (D) were
imaged for 15 min using Fura-2. Arrows represent treatment with 5 mM TG, and either 100 mM RES (black), 100 mM quercetin (blue), 100 mM EGCG (red) or vehicle (green) at
1 min and 6 min, respectively. Quercetin, EGCG and vehicle all showed statistically signiﬁcant differences in [Ca2þ]i changes from RES in PDF cells (* signiﬁes a statistically
signiﬁcant difference from RES at po0.01,** signiﬁes that RES-treated cells differed signiﬁcantly from vehicle-treated cells at po0.01). MDA cells (E) were imaged for 15 min
using Fura-2. Arrows represent treatment with 5 mM TG, and either 100 mM RES (black), 100 mM quercetin (blue), 100 mM EGCG (red) or vehicle (green) at 1 min and 6 min,
respectively. Quercetin, EGCG and vehicle all showed statistically signiﬁcant differences in [Ca2þ]i changes from RES in MDA cells (* signiﬁes a statistically signiﬁcant
difference from RES at po0.01,** signiﬁes that RES-treated cells differed signiﬁcantly from vehicle-treated cells at po0.01). Differences in calcium response to quercetin and
EGCG indicate that neither molecule inhibits PMCA to the same degree as RES.
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question the validity of research conducted using RES and Fura-2
together. In contrast with these studies, our data illustrates that
treatment of 100 mM RES in MDA cells increases the 340 nm signal
and decreases the 380 nm signal (Fig. 3A).
To further verify that RES does not interfere with Fura-2, we
performed in vitro measurements of the emission spectra of RES
and Fura-2 when excited at 340 nm and 380 nm in Ca2þ-free, and
1 mM Ca2þ solutions. We measured Fura-2 ﬂuorescence at its
estimated intracellular concentration of 5 mM [30]. To our knowl-
edge, the intracellular concentration of RES has not been reported;
therefore, we measured the spectra at 100 mM, which is close to
the upper limit for RES solubility in aqueous solutions. Fura-2
ﬂuorescence when excited at 340 nm and 380 nm in a 1 mM Ca2þ
solution was approximately 100 and 15 times larger than RES at
the same wavelengths, respectively. In the absence of calcium,
340 nm and 380 nm Fura-2 510 nm emission was 120 and 140 fold
higher than that of 100 mM RES (data not shown). RES, in the same
buffer and at a concentration 20 times higher than Fura-2, only
emitted approximately 1% of the signal that Fura-2 did, therefore
any additive effect from RES would be minor (Fig. 3B). However,
synergistic effects between RES and Fura-2, if any, could explain
why previous studies have seen a calcium-independent spike in
the Fura-2 calcium-bound signal in RES-treated cells.
Although we estimated that the additive effect of RES on Fura-2
ﬂuorescence would be minimal, we wanted to ensure that there
was no synergistic effect by RES on Fura-2 ﬂuorescence. Solutionswere made containing 5 mM Fura-2 alone and Fura-2 with 1, 10, 25,
50, 75, and 100 mM RES. RES signiﬁcantly decreased the Fura-2
510 nm emission when excited at 340 nm (Fig. 4) at concentrations
above 50 mM in Ca2þ-free solution and above 25 mM in 1 mM Ca2þ
solution. RES showed no statistically signiﬁcant effect on Fura-2
ﬂuorescence when excited at 380 nm in either the Ca2þ-free or
1 mM Ca2þ solution (Fig. 4). The diminished Fura-2 ﬂuorescence
by RES is likely due to spectral overlap as RES absorbance spectra
shows signiﬁcant absorbance at 340 nm, but no absorbance at
380 nm [31]. Taken together, this data indicates that RES does not
increase the calcium-bound ﬂuorescence of Fura-2, but rather has
a quenching effect, which may mask the full magnitude of the
RES-induced calcium signal.
Although this data is sufﬁcient to conclude that RES does not
interfere with Fura-2 ﬂuorescence in vitro, it does not address
what occurs in vivo. To provide evidence that RES is not directly
interfering with Fura-2 in vivo, we co-loaded cells with the calcium
chelator, BAPTA, and Fura-2 (Fig. 1B). BAPTA pretreatment elim-
inates any effects of [Ca2þ]i changes in the cell by sequestering
free, cytosolic Ca2þ ions. Upon treatment of the co-loaded cells
with RES, no change in Fura-2 ﬂuorescence was observed, in-
dicating that the RES-induced change in Fura-2 ﬂuorescence is
Ca2þ-dependent and not artifact. Because the Fura-2 340 nm/
380 nm ratio is higher in the 1 mM Ca2þ solution than in the
Ca2þ-free solution, despite spectral overlap between Fura-2 and
RES, we conclude that, in our hands, the RES-induced calcium
signal appears to be reﬂective of the changes in [Ca2þ]i due to
Fig. 3. Emission spectra of RES and Fura-2. Separate measurements (A) of 340 nm
(Ca2þ-bound, blue) and 380 nm (Ca2þ-free, orange) signal intensity in MDA cells
with 5 mM TG and 100 mM RES treatments at 1 min and 6 min, respectively, as in-
dicated by the arrows. This data (A) is representative of all experiments conducted
at these concentrations. Emission spectra (B) in 1 mM Ca2þ solution when excited
at 340 nm of 100 mM RES (blue), and 5 mM Fura-2 (yellow).
Fig. 4. The direct effects of RES on Fura-2 ﬂuorescence. Solutions containing
5 mM Fura-2 pentasodium salt were titrated with RES at 0 mM (blue), 1 mM (orange),
10 mM (gray), 25 mM (yellow), 50 mM (red), 75 mM (green), and 100 mM (purple). The
samples were excited at 340 nm and 380 nm and the emission of each sample was
measured at 510 nm. Each measurement was performed in triplicate in PBS with
0 mM Ca2þ or 1 mM Ca2þ as outlined in the ﬁgure (*signiﬁes a statistically sig-
niﬁcant difference from Fura-2 emission at 510 nm at po0.01). Error bars re-
present the standard deviation.
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In this paper, we demonstrate that RES inhibits PMCA in a
dose-dependent manner. PMCA is an important therapeutic targetgiven that changes in PMCA activity and expression are prevalent
in diseased cells. Current putative therapeutic options for PMCA
inhibition are generally limited by their non-speciﬁcity to PMCA
isoforms and/or impermeability to the cell [7,32]. The novel dis-
covery of RES as a PMCA inhibitor sets the foundation for further
study on the effects of RES or RES derivatives on diseases with
modulated PMCA activity or expression. RES has also been shown
to be cell-permeable and, as a result, may act on PMCA via a dif-
ferent mechanism than current PMCA inhibitors [33]. We also
demonstrate that RES and Fura-2 are compatible for simultaneous
use, thereby conﬁrming the validity of the measurement methods
used in this study. We illustrate that inhibition of PCMA is unique
to RES in comparison to two polyphenols of similar chemical
structure, EGCG and quercetin. Our data suggest that other poly-
phenolic compounds do not demonstrate PMCA inhibition. The
use of binding assays to explore the effects of such structural
differences on the RES-PMCA interaction could yield the in-
formation necessary to synthesize RES derivatives capable of in-
hibiting speciﬁc PMCA isoforms without the off-target effects
normally induced by RES.
One of the known effects of RES on tumorigenic cells is apop-
tosis. Previous studies have indicated that the apoptotic response
to RES is tumor-cell speciﬁc [33–36]. Our results indicate that tu-
mor-speciﬁc apoptosis induced by RES is not solely the result of
PMCA inhibition because the associated changes in [Ca2þ]i are
similar in both tumorigenic and non-tumorigenic cells. We draw
this conclusion because PMCA inhibition proﬁles are similar in
non-tumorigenic PDF and tumorigenic MDA cells. However, pre-
vious studies have shown that calcium signaling is an essential
part of the RES-dependent apoptotic effect on tumor cells by using
the intracellular Ca2þ chelator, BAPTA, to block RES-dependent
apoptosis [37]. Indeed, further research in other cell types, animal
and human models will be needed to understand the relation
between PMCA inhibition and the RES-dependent apoptotic re-
sponse. Given that PMCA is inhibited in tumorigenic and non-tu-
morigenic cells, but apoptosis is differentiated by cell type, we
postulate that cancer cells have modiﬁed or additional
Ca2þ-binding proteins downstream from the calcium signaling
event that trigger the apoptotic response.
Another section of this study worth further exploration in-
volves the separate isoforms of PMCA. As previously mentioned,
PMCA exists in four isoforms, with each isoform possessing mul-
tiple splice variants. PMCA1 and 4 are generally universally ex-
pressed and serve housekeeping functions whereas PMCA2 and
3 are differentiated by cell type [38]. Speciﬁc PMCA-related dis-
eases are typically associated with the modiﬁcation of one or more
PMCA isoforms [6,7]. In MDA cells, PMCA2 and 4 are upregulated
[6], which may confer cancer the ability to avoid the high [Ca2þ]i
levels associated with apoptosis. We speculate that one of the
many facets of RES-induced apoptosis may be the demonstrated
inhibition of PMCA isoforms in cancer cells, thus inducing the
sufﬁciently high [Ca2þ]i necessary for apoptosis. In relation to our
data, PMCA1 and 4 are present in PDF cells, while PMCA1, 2 and
4 are present in MDA cells [39,40]. Because RES caused an increase
in [Ca2þ]i in a similar fashion in both cell types, there are several
possibilities as to the isoform speciﬁcity of RES as a PMCA in-
hibitor. As PMCA1 and 4 are present in both cell types, RES may be
acting to inhibit one or both of these isoforms. The possibility also
exists that RES is a pan-PMCA inhibitor, meaning that it inhibits all
isoforms of PMCA. It seems unlikely that RES is acting as a PMCA2-
speciﬁc inhibitor as both cell types react similarly to RES treatment
in our experiments while PMCA2 is found in MDA cells and not in
PDF cells. Further study of RES and development of RES derivatives
may yield isoform-speciﬁc PMCA inhibitors with the capability of
acting as non-toxic treatments for cancers and other diseases with
upregulated PMCA proﬁles.
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Our data more fully elucidates the relationship between RES
and PMCA by demonstrating RES-dependent PMCA inhibition in
primary human ﬁbroblasts and MDA-MB-231 breast cancer cells.
Additionally, our data shows that PMCA inhibition is novel to RES
in comparison to other naturally occurring polyphenols, EGCG and
quercetin. Previous studies have shown that RES and Fura-2 have
spectral overlap, which led to an artifactual rise in the Fura-2
calcium measurement. However, we demonstrate that Fura-2 can
be used to measure intracellular calcium changes induced by RES.
Further study of PMCA and RES may yield isoform-speciﬁc PMCA
inhibitors capable of non-toxic treatment of speciﬁc diseases.Conﬂict of interest
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